Brief: Cantargia Reports Positive Preclinical Effects In Atherosclerosis Demonstrating Potential Of CAN10 In Cardiovascular Disease
22/05/2022 08:05
May 22 (Reuters) - Cantargia AB CANTA.ST :
* CANTARGIA REPORTS POSITIVE PRECLINICAL EFFECTS IN
ATHEROSCLEROSIS DEMONSTRATING POTENTIAL OF CAN10 IN
CARDIOVASCULAR DISEASE
* CANTARGIA - LOOKING FORWARD TO FIRST HUMAN TRIAL OF CAN10
IN
EARLY 2023
Source text for Eikon: ID:nWkr1lqLwq
Further company coverage: CANTA.ST
((Reuters.briefs@thomsonreuters.com;))
Recent news on Cantargia AB
See all newsBrief: Cantargia Publishes Nadunolimab CANFOUR Study Data
Brief: Cantargia Announces Outcome Of Rights Issue, Raising About SEK 75 Mln
Brief: Cantargia Carries Out Rights Issue, Enters Loan Agreement
Brief: Cantargia Q1 Operating Loss Narrows To SEK 36.9 Mln
Brief: Cantargia: Early Results From Phase 1B/2A Nadunolimab Trial In MDS And AML